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Nanostructured, self-assembling peptides hold promise for a variety of regenerative medical applications such as 3D cell culture
systems, accelerated wound healing, and nerve repair. The aim of this study was to determine whether the self-assembling
peptide K5 can be applied as a carrier of anti-inﬂammatory drugs. First, we examined whether the K5 self-assembling peptide
itself can modulate various cellular inﬂammatory responses. We found that peptide K5 signiﬁcantly suppressed the release of
tumor-necrosis-factor- (TNF-) α and prostaglandin E2 (PGE2) from RAW264.7 cells and peritoneal macrophages stimulated
by lipopolysaccharide (LPS). Similarly, there was inhibition of cyclooxygenase- (COX-) 2 mRNA expression assessed by real-
time PCR, indicating that the inhibition is at the transcriptional level. In agreement with this ﬁnding, peptide K5 suppressed
the translocation of the transcription factors activator protein (AP-1) and c-Jun and inhibited upstream inﬂammatory eﬀectors
including mitogen activated protein kinase (MAPK), p38, and mitogen-activated protein kinase kinase 3/6 (MKK 3/6). Whether
this peptide exerts its eﬀects via a transmembrane or cytoplasmic receptor is not clear. However, our data strongly suggest that the
nanostructured, self-assembling peptide K5 may possess signiﬁcant anti-inﬂammatory activity via suppression of the p38/AP-1
pathway.
1.Introduction
Inﬂammation is one of the body innate immune responses
and is mainly mediated by macrophages. When viruses
or bacteria infect the body, signiﬁcant cooperation among
macrophages, dendritic cells, B cells, and T cells is required.
Various inﬂammatory molecules, such as cytokines (e.g.,
tumor-necrosis-factor- (TNF-) α), chemokines, and medi-
ators (including nitric oxide (NO) and prostaglandin E2
(PGE2)), are known to play critical roles in managing
crosstalk between immune cells in both acute and chronic
responses [1, 2]. In this regard, the initial activation of
macrophages in inﬂammatory events could be an important
step.
Initiation of the macrophage inﬂammatory process is
triggered by the activation of receptors such as Toll-like
receptor (TLR) 4 and TLR3 through the binding of their lig-
ands,suchaslipopolysaccharide(LPS)andpoly(I:C),respec-
tively [3]. A series of intracellular signaling events follows,
managed by the activities of nonreceptor protein tyrosine
kinases and mitogen-activated protein kinases (MAPKs),
including ERK (extracellular signal-related kinase), p38, and
JNK (C-Jun N-terminal kinase), as well as the activation and
upregulation of transcription factors (e.g., nuclear-factor-
(NF-) κB and activator-protein- (AP) 1) [4, 5]. Eventually,
these responses lead macrophages to be transcriptionally
activated to express proinﬂammatory genes encoding such2 Mediators of Inﬂammation
cytokines as tumor-necrosis-factor- (TNF-) α, inducible NO
synthase (iNOS), and cyclooxygenase- (COX-) 2 [6–9].
Although it is well known that inﬂammation is a repre-
sentative defense mechanism in the body, severe inﬂamma-
toryresponsesmayleadtoanumberofseriousdiseases,such
as cancer, diabetes, septic shock, rheumatoid arthritis, and
atherosclerosis [8, 10–12]. Eﬀective modulation of the acute
or chronic inﬂammatory responses could be used to cure or
prevent such diseases; each of the biochemical elements of
the inﬂammatory signaling pathway may be considered as an
anti-inﬂammatory target for new drug development.
Self-assembling peptide nanoﬁber-based hydrogels with
a broad range of biomedical and biotechnological applica-
tions have been widely studied [13, 14]. Short peptides with
8t o1 6r e s i d u e so r2 . 5t o5n mi nl e n g t hh a v eb e e nf o u n d
toself-assembleintohydrogen-formingnanoﬁbersunderthe
proper conditions, including pH and ionic strength of the
medium [15]. Due to their structural merits, such hydrogel
systems have been applied to 3D tissue cultures and tissue
engineering research systems [16, 17]. An interesting phar-
macological application of this nanoﬁber technology is as a
biocompatible drug delivery system controlling the release
of small molecules or peptides/proteins [14]. Controlling
the release rates of small molecules and peptides/proteins
through various hydrogels is a critical aspect of biomaterials
science.
Even though self-assembled peptide nanoﬁbers are
more advantageous than synthetic drug delivery polymers,
it is necessary to test whether the peptide components
are immunogenic or inﬂammation-inductive in the body.
Because only a few studies regarding the eﬀects of peptide
nanoﬁbers on immunological responses have been reported,
we explored the immunoregulatory role of a representative
peptide nanoﬁber (peptide K5) by measuring its inﬂamma-
tion regulation activity in vitro.
2.MaterialsandMethods
2.1. Materials. Peptide K5 was designed and prepared as
previously described [18, 19]. (3-4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide, a tetrazole (MTT), dex-
tran sulfate sodium (DSS), and lipopolysaccharide (LPS, E.
coli 0111:B4) were purchased from Sigma Chemical Co. (St.
Louis, MO). SB203580 was obtained from Calbiochem (La
Jolla, CA). Luciferase constructs containing promoters sen-
sitive to NF-κB and AP-1 were gifts from Professors Chung
Hae Young (Pusan National University, Pusan, Republic of
Korea) and Man Hee Rhee (Kyungpook National University,
Daegu, Republic of Korea). Enzyme immunoassay (EIA) kits
and enzyme-linked immunosorbent assay (ELISA) kits for
determining PGE2 and TNF-α were purchased from Amer-
sham (Little Chalfont, Buckinghamshire, UK). Fetal bovine
serum and RPMI1640 were obtained from GIBCO (Grand
Island, NY). RAW264.7 and HEK293 cells were purchased
from the ATCC (Rockville, MD). All other chemicals were
of analytical grade and were obtained from Sigma. Phospho-
speciﬁc or total antibodies against c-Fos, c-Jun, extracellular
signal-related kinase (ERK), c-Jun N-terminal kinase (JNK),
p38, mitogen-activated protein kinase kinase 3/6 (MKK3/6),
TGF-β-activated kinase 1 (TAK1), interleukin-1 receptor-
associated kinase 1 (IRAK1), inhibitor of κBα (IκBα), γ-
tubulin, and β-actin were obtained from Cell Signaling
(Beverly, MA).
2.2. Animals. C57BL/6 male mice (6 to 8 weeks old, 17
to 21g) were obtained from Daehan Biolink (Chungbuk,
RepublicofKorea)andhousedinplasticcagesunderconven-
tional conditions. Water and pellet diets (Samyang, Daejeon,
Republic of Korea) were available ad libitum. Studies were
performed in accordance with guidelines established by
the Kangwon University Institutional Animal Care and Use
Committee.
2.3. Preparation of Peritoneal Macrophages. Peritoneal exu-
d a t e sw e r eo b t a i n e df r o mC 5 7 B L / 6m a l em i c e( 7t o8w e e k s
old, 17 to 21g) by lavaging four days after intraperitoneal
injection of 1mL of sterile 4% thioglycolate broth (Difco
Laboratories, Detroit, MI) as reported previously [20]. After
washing with RPMI 1640 medium containing 2% FBS,
peritoneal macrophages (1 × 106 cells/mL) were plated in
100mm tissue culture dishes for 4h at 37◦Ci na5 %C O 2
humidiﬁed atmosphere.
2.4. Cell Culture. Peritoneal macrophages and cell lines
(RAW264.7 and HEK293 cells) were cultured with
RPMI1640 medium supplemented with 10% heat-
inactivated fetal bovine serum (Gibco, Grand Island, NY),
glutamine, and antibiotics (penicillin and streptomycin)
at 37◦C under 5% CO2.F o re a c he x p e r i m e n t ,c e l l sw e r e
detached with a cell scraper. At the cell density used for
experiments (2 × 106 cells/mL), the proportion of dead cells
w a sl e s st h a n1 %a sm e a s u r e db yT r y p a nb l u ed y ee x c l u s i o n .
2.5. NO, PGE2,a n dT N F - α Production. After preincubation
of RAW264.7 cells or peritoneal macrophages (1 × 106
cells/mL) for 18h, cells were pretreated with Peptide K5 (0
to 400μg/mL) for 30min and were further incubated with
LPS (1μg/mL) for 24h. The inhibitory eﬀect of peptide
K5 on NO, PGE2,a n dT N F - α production was determined
by analyzing NO, PGE2,a n dT N F - α levels with the Griess
reagent and enzyme linked immunosorbent assay (ELISA)
kits as described previously [21, 22].
2.6. Cell Viability Test. After preincubation of RAW264.7
cells (1 × 106 cells/mL) for 18h, the peptide K5 (0 to
100μg/mL) was added to the cells and incubated for 24h.
The cytotoxic eﬀect of the peptide K5 was then evaluated by
a conventional MTT assay, as reported previously [23, 24].
At 3h prior to culture termination, 10μLo fM T Ts o l u t i o n
(10mg/mL in phosphate-buﬀered saline, pH 7.4) was added
to each well, and the cells were continuously cultured until
termination of the experiment. The incubation was halted
by the addition of 15% sodium dodecyl sulfate into each
well, thus solubilizing the formazan [25]. The absorbance at
570nm (OD570−630) was measured using a Spectramax 250
microplate reader.Mediators of Inﬂammation 3
Table 1: Sequences of primers used in real-time PCR analysis.
Gene Primer sequences
iNOS F5  -CCCTTCCGAAGTTTCTGGCAGCAGC-3 
R5  -GGCTGTCAGAGCCTCGTGGCTTTGG-3 
COX-2 F5  -CACTACATCCTGACCCACTT-3 
R5  -ATGCTCCTGCTTGAGTATGT-3 
GAPDH F5  -CACTCACGGCAAATTCAACGGCAC-3 
R5  -GACTCCACGACATACTCAGCAC-3 
2.7.mRNAAnalysisbyReal-TimePolymeraseChainReactions
(RT-PCR). To determine cytokine mRNA expression levels,
total RNA was isolated from LPS-treated RAW264.7 cells
with the TRIzol Reagent (Gibco BRL) according to the
manufacturer’s instructions. Total RNA was stored at −70◦C
until use. Quantiﬁcation of mRNA was also performed using
real-time RT-PCR with SYBR Premix Ex Taq (Takara, Japan)
and a real-time thermal cycler (Bio-Rad, Hercules, CA) as
reported previously [26, 27]. The results were expressed as
a ratio of optical density to GAPDH. The primers (Bioneer,
Daejeon, Republic of Korea) used are indicated in Table 1.
2.8. Luciferase Reporter Gene Activity Assay. HEK293 cells (1
× 106 cells/mL) were transfected with 1μg of plasmids con-
taining NF-κB-Luc or AP-1-Luc along with β-galactosidase
using the calcium phosphate method in a 12-well plate
according to the manufacturer’s protocol [28]. The cells
were used for experiments 48h after transfection. Luciferase
assays were performed using the Luciferase Assay System
(Promega) as reported previously [29].
2.9. Preparation of Total Lysates and Nuclear Extracts and
Immunoblotting. Preparation of total lysates and nuclear
extracts from LPS-treated RAW264.7 cells pretreated with
peptide K5 was performed using a previously published
method [30]. Immunoblot analysis of levels of phosphory-
lated or total transcription factor (AP-1(c-Fos, c-Jun), p-
FRA-1), Lamin A/C, MAPK (ERK, p38, and JNK), MKK 3/6,
TAK-1, IRAK-1, IκBα,a n dβ-actin was performed according
to published methods [31, 32].
2.10.StatisticalAnalysis. Data(Figures1,2,and4),expressed
as mean ± standard deviation (SD), were calculated from
one (n = 6) of two independent experiments. Other data
are representative of three diﬀerent experiments with similar
results. For statistical comparisons, results were analyzed
using analysis of variance/Scheﬀe’s post hoc test, and the
Kruskal-Wallis/Mann-Whitney test. All P values <0.05 were
considered statistically signiﬁcant. All statistical tests were
carried out using the computer program SPSS (SPSS Inc.,
Chicago, IL).
3. Results andDiscussion
Peptide K5 is a representative peptide known to be self-
assembled and to form nanoﬁbers that can be used as 3D
scaﬀolds for tissue engineering or drug delivery [14, 17].
Thus far, no one has tested whether this peptide itself can
induce an immunological response, but it is important for us
todeterminewhetherthisnanoﬁberisimmunogenicpriorto
usingitasadrugdeliverysystem.Therefore,inthisstudy,the
regulatory activity of peptide K5 on macrophage-mediated
inﬂammatory responses was examined under LPS treatment
conditions.
Our data suggest that peptide K5 can act as a thera-
peutic molecule with anti-inﬂammatory properties. Thus,
K5 suppressed TNF-α production in a concentration-
dependent manner in both in RAW264.7 cells (Figure 1(a))
and in bone marrow-derived macrophages stimulated by
LPS (Figure 1(b)). The peptide also showed signiﬁcant inhi-
bition of PGE2 production in LPS-treated RAW264.7 cells
(Figure 1(c)). However, peptide K5 did not suppress either
NO release from LPS-treated RAW264.7 cells (Figure 1(d))
or phagocytic uptake of FITC-dextran by RAW264.7 cells
(Figure 1(e)), indicating that not all macrophage activation
pathways are blocked by the peptide. Because K5 did not
induce cytotoxicity at up to 100μg/mL under the conditions
studied (Figure 1(f)), all inhibitory activities seem to be
due to a speciﬁc pharmacological action. The suppressive
activities were much stronger than or comparable to those
of previously reported peptides such as an immunomod-
ulatory peptide (CP), human β-defensin 3, HBD-2, and
enantiomeric 9-mer peptide [33, 34]. Considering these
points, it is reasonable that peptide K5 could be used as an
anti-inﬂammatory therapeutic.
Because drug development requires understanding the
molecular mechanism of a drug pharmacological action,
we explored the inhibitory mechanism of peptide K5. To
determine whether peptide K5 is able to suppress LPS-
induced inﬂammatory responses at the transcriptional or
translational levels, the mRNA levels of the inﬂammatory
genes iNOS and COX-2 induced by LPS were measured by
real-time PCR. Peptide K5 only blocked mRNA expression
of COX-2 up to 60% at 100μg/mL (Figure 2), implying
that the inhibition of PGE2 production could be due
to the blockade of transcriptional activation mediated by
inﬂammatory transcription factors, such as NF-κB and AP-1
[35]. To determine which transcription factors are targeted
by peptide K5, nuclear proteins were analyzed. Interestingly,
at 30 to 60min, peptide K5 markedly diminished nuclear
levels of c-Jun, while Fra-1 and c-Fos levels were not altered
(Figure 3(a)), indicating that, among the diﬀerent AP-1 fam-
ilyproteins, c-Juncouldbeatranscriptional targetofpeptide
K5. To identify the molecular target of peptide K5, signaling
events upstream of AP-1 translocation were continuously
evaluated. Intriguingly, at 30 to 60min, peptide K5 markedly
suppressed the phosphorylation of p38, a critical enzyme
for c-Jun translocation (Figure 3(b)), although this pep-
tide remarkably enhanced p38 phosphorylation. Meanwhile,
because there was no inhibition of IκBα phosphorylation,
and rather it has been enhanced at 5, 30, and 60min
(Figure 3(b)), we expected that NF-κB, a major transcription
factor activated under inﬂammatory conditions, would not
be blocked by peptide K5. Indeed, the peptide did not
suppress NF-κB translocation (data not shown). So far, we4 Mediators of Inﬂammation
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Figure 1: Eﬀect of peptide K5 on the production of inﬂammatory mediators. (a), (b), (c), and (d) Levels of NO, PGE2,a n dT N F - α were
determined by Griess assay, EIA, and ELISA from culture supernatants of RAW264.7 cells or peritoneal macrophages treated with peptide K5
(0 to 100μg/mL) and LPS (1μg/mL) for 6 (TNF-α)o r2 4( N Oa n dP G E 2) h. (e) Phagocytic uptake levels of FITC-dextran were determined
by ﬂow cytometric analysis using RAW264.7 cells treated with peptide K5 (0 to 100μg/mL) and FITC-dextran (1μg/mL) for 6 (TNF-α)o r2 4
(NO and PGE2) h. (e) Cell viability of RAW264.7 cells and peritoneal macrophages was determined by MTT assay. ∗P<0.05 and ∗∗P<0.01
compared to control.
could not understand why the phosphorylation of IκBα was
enhanced by the treatment of peptide K5. Whether this
peptide is able to stimulate the activity of upstream signaling
e n z y m e ss u c ha sA k ta n dI κBα kinase (IKK) for this event
or increase the protein level of IκBα by suppression of its
cleavage pathway could be considered to be tested in the
following experiments.
To determine whether peptide K5 can block events
upstream of p38, the phosphorylation patterns of several
upstream enzymes were investigated. Peptide K5 inhibited
the phosphorylation of MKK3/6, an upstream kinase of p38
[36], at 5min, while the activation of its upstream enzymes,
TAK1 and IRAK1, as assessed by measuring phospho-TAK1
and a degraded form of IRAK1 [37], was not diminished
(Figure 3(c)). Peptide K5 also showed an inhibitory pattern
of luciferase activity mediated by AP-1 (Figure 3(d)), as
assessed by a reporter gene assay with AP-1 promoter.
Therefore, our data strongly suggest that the molecular
target of peptide K5 seems to be a complex of AP-1 (c-
Jun), p38, MKK3/6 kinase, and TAK1 in LPS signaling.
However, whether this peptide can block TAK1 enzymatic
activity either directly or indirectly is not yet clear. Detailed
studiesusing puriﬁedTAK1willbeconductedtoaddressthis
issue.Mediators of Inﬂammation 5
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Figure 2: Eﬀect of peptide K5 on the mRNA expression of proinﬂammatory genes. (a) and (b) The mRNA levels of iNOS and COX-2 were
determined by real-time PCR. ∗P<0.05 compared with controls.
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determined by Western blot analysis using antibodies against total protein. (d) HEK293 cells cotransfected with plasmid constructs NF-κB-
Luc, or AP-1-Luc (1μg/mL each) and β-gal (as a transfection control) were treated with SB203580 (25μM) in the presence or absence of
TNF-α (20ng/mL) for NF-κB activation or PMA (10ng/mL) for AP-1 activation. Luciferase activity was measured using a luminometer.
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Figure 5: Putative inhibitory pathway of LPS-activated inﬂammatory signaling responses by peptide K5.
The functional signiﬁcance of the p38/MKK3/6/TAK1
pathway for AP-1 activation and inﬂammatory responses
has been well deﬁned [36]. To conﬁrm its role under
our experimental conditions, a selective inhibitor of p38,
SB203580, was employed and tested under the same con-
ditions. Neither K5 nor the p38 inhibitor blocked NO
production (Figure 4(b)). In contrast, SB203580 markedly
suppressed both PGE2 (Figure 4(b))a n dT N F - α production
(data not shown), suggesting that the p38 pathway may be
a critical component in regulating the release of PGE2 and
TNF-α in LPS-treated macrophages.
In general, it is known that proteins and peptides are
not able to penetrate the cell membrane due to their sizes
and charges. Small hydrophobic molecules exhibiting anti-
inﬂammatory activities, however, are membrane-permeable
compounds and are expected to easily modulate cytosolic
target enzymes. In this regard, the possibility that peptide K5
can be transported into the cytoplasm by a speciﬁc trans-
porter seems plausible. Several receptors, such as PEPT1,
OATP1A2, OATP1B1, OATP1B3, and OATP2B1, have been
identiﬁed as transporters of peptide molecules [38, 39].
Because some of these receptors, including PEPT1, haveMediators of Inﬂammation 7
been reported to be involved in inﬂammatory responses,
it is necessary to test whether these transporters and the
relevant signaling pathways are critical for the pharmacology
of peptide K5. Further studies will be conducted to address
these points.
Unlike small-molecule drugs, the therapeutic use of
peptide-based drugs is hindered by cost, stability, phar-
macokinetics, and obscure targeting. Nonetheless, some
peptidessuchasGLP-1analogs,extracellularmatrixprotein-
derived peptides such as acetylated Pro-Gly-Pro (Ac-PGP)
[40], and integrin-binding N-terminal peptide [41]h a v e
been reported to have anticancer, antiseptic shock, and
antitumorigenic activities and were subsequently developed
as promising peptide drugs. Indeed, some peptide-type
drugs have already been used as glycopeptide-type antibi-
otics (e.g., vancomycin) [42]. However, compared with
small-molecule drugs having subnanomolar potency, it is
diﬃcult to develop a low-potency peptide into a drug.
Recent studies have focused on developing special drug
delivery apparatuses using peptides [14]. Peptide K5 is a
candidate peptide for drug delivery; it is a self-assembling
nanopeptideformingahydrogelandisknowntobegenerally
nonimmunogenic,nonthrombogenic,andapplicabletosuch
noninvasive therapies as void ﬁlling [14, 18, 19]. Through
these properties, self-assembling peptides have been nom-
inated as scaﬀolds for 3D cell culturing systems, regenera-
tive medicine applications, and drug delivery applications
[43, 44]. Although such applicable features are suﬃcient
to warrant use of these peptides, the anti-inﬂammatory
property of peptide K5 could provide an additive beneﬁt
when used as an anti-inﬂammatory drug delivery system.
In particular, because this peptide has been shown to block
the p38/AP-1 pathway in the LPS/TLR4 response, drugs with
inhibitory activities on the activation of NF-κB or IRF-3,
which aﬀect the production of NO and IFN-β,w i l lh e l pt o
synergize total anti-inﬂammatory responses. This hypothesis
will be evaluated using several in vivo inﬂammatory models,
such as DSS-induced colitis and collagen-type-II-generated
arthritis.
In summary, we have demonstrated that peptide K5
can strongly block macrophage-mediated inﬂammatory
responses, such as the production of TNF-α and PGE2,
during the activation of TLR4. In particular, peptide K5
selectively diminishes the activation of AP-1 by suppression
of upstream signaling enzymes, such as MKK3/6 and TAK1
(Figure 5). Considering that this peptide is a self-assembling
drug delivery carrier, it is possible that peptide K5 could be
developed as a carrier of NF-κB inhibitory drugs and act
synergistically to combat inﬂammation. To investigate this
possibility,weplantoconductadditionalinvivoeﬃcacytests
using models of chronic inﬂammatory disorders (e.g., colitis
and arthritis).
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